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Objective
To investigate the differences in the therapeutic approach
to juvenile dermatomyositis (JDM) between pediatric
rheumatology centers in Europe (EU) and Latin America
(LA).
Methods
490 patients with JDM and disease duration > 2 years seen
in 27 centers in EU (Italy, UK) and LA (Argentina, Brazil,
Mexico) after 1980 were enrolled in a multinational, mul-
ticenter study aimed to investigate the long-term disease
outcome. Median follow-up duration was 7.7 years (range
2–25.2 years). Gender ratio, onset age, and follow-up
duration were comparable between EU and LA patients.
At study visit, EU patients had a greater frequency of active
disease, as measured with MDAA (51.1% vs. 35.2%) and
DAS (64.8% vs. 54%), whereas LA patients had a greater
frequency of muscle weakness, as measured with the
CMAS (62.9% vs. 44.3%), and muscle damage, as meas-
ured with the MDI (41% vs. 30.1%).
Results
Table 1 shows the frequency of drugs administered to
JDM patients in EU and LA centers.
Conclusion
Use of pulse iv steroids, CyA, AZA and CPM was more
common in EU centers, whereas LA centers used more fre-
quently MTX and AM. EU and LA centers administered iv
Ig with equal frequency.
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Table 1: Frequency of drugs administered to JDM patients in EU and LA centers
Oral/iv steroids Pulse iv steroids MTX CyA Iv Ig AM AZA Oral CPM Pulse iv CPM
EU (N = 246) 97.6 50 50.8 35 17.1 26 13.4 5.3 8.5
LA (N = 236) 99.6 33.2 61.4 15.7 17.4 39 5.9 2.1 4.2
MTX: methotrexate; CyA: cyclosporine A; AM: antimalarials; AZA: azathioprine; CPM: cyclophosphamide